SCHEMBL23167369

SCHEMBL23167369

O=C(NO)c1cnc(Cn2ccc3cc(C(=O)NC4CC4)cnc32)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 2/20 0.41
▸ HDAC2 Q92769 2/20 0.41
▸ MCHR1 Q99705 5/20 0.40
▸ MAPK14 Q16539 4/20 0.40
▸ CYP2C9 P11712 3/20 0.40
▸ MAPK11 Q15759 3/20 0.40
▸ HDAC1 Q13547 2/20 0.39
▸ HDAC6 Q9UBN7 2/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ BUB1 O43683 1/20 0.39
▸ PRKACG P22612 1/20 0.39
▸ MAPKAPK2 P49137 1/20 0.39
▸ ACSL5 Q9ULC5 1/20 0.39
▸ STK24 Q9Y6E0 1/20 0.39
▸ HPGDS O60760 2/20 0.39
▸ PDPK1 O15530 1/20 0.39
▸ HDAC8 Q9BY41 1/20 0.38
▸ CXCR4 P61073 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29779623 1.00 HDAC3 (0.41) HDAC3HDAC2MCHR1MAPK14CYP2C9
SCHEMBL23167484 0.91 FGFR1 (0.45) HDAC3HDAC2MCHR1HPGDSPDPK1
SCHEMBL25138359 0.90 HPGDS (0.42) MCHR1MAPK14CYP2C9MAPK11BUB1
SCHEMBL23201985 0.81 SLC22A12 (0.44) HDAC3HDAC2HDAC1HDAC6HDAC4
SCHEMBL23167363 0.74 FGFR1 (0.48) HDAC3HDAC2HDAC1
SCHEMBL23167492 0.73 FGFR1 (0.48) HDAC3HDAC2CYP2C9HDAC6HDAC8
SCHEMBL18109083 0.68 HDAC6 (0.43) HDAC3HDAC2HDAC1HDAC6HDAC4
SCHEMBL23203467 0.67 MTNR1A (0.46) HDAC3HDAC2HDAC1HDAC6HDAC4
SCHEMBL23202566 0.67 HDAC6 (0.43) HDAC3HDAC2HDAC1HDAC6HDAC4
SCHEMBL18125611 0.66 HDAC6 (0.47) HDAC3HDAC2HDAC1HDAC6HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2023-04-20 — — US disclosed
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2023-04-20 — — US disclosed
EP-4037670-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF Tenaya Therapeutics, Inc. (US) 2022-08-10 — — EP disclosed
WO-2021067859-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2021-04-08 — — WO disclosed
WO-2021067859-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF TENAYA THERAPEUTICS, INC. (US) 2021-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230123856-A1 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF SLC28A1, SLC5A1, SLC9A5 HDAC3 367/4885HDAC2 295/4885MCHR1 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback